Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

BACKGROUND: RECORD-3 assessed non-inferiority of progression-free survival (PFS) with everolimus vs sunitinib in previously untreated patients with metastatic renal cell carcinoma. Baseline plasma sample collection and randomised design enabled correlation of circulating biomarkers with efficacy. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800293/
https://www.ncbi.nlm.nih.gov/pubmed/26908330
http://dx.doi.org/10.1038/bjc.2016.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800293/
https://www.ncbi.nlm.nih.gov/pubmed/26908330
http://dx.doi.org/10.1038/bjc.2016.21

Ejemplares similares